The global in-vitro colorectal cancer screening tests market size reached USD 1,049.2 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,658.7 Million by 2033, exhibiting a growth rate (CAGR) of 4.96% during 2025-2033.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024
|
USD 1,049.2 Million |
Market Forecast in 2033
|
USD 1,658.7 Million |
Market Growth Rate 2025-2033 | 4.96% |
In-vitro colorectal cancer screening tests are diagnostic procedures performed to detect adenomas, polyps and symptoms of colorectal cancer. Colorectal cancer refers to a medical condition that is characterized by the abnormal growth of cells in the large intestine, colon and rectum. Fecal occult blood (FOB), lateral flow immuno, transferrin assays, methylated gene, biomarker and guaiac FOB stool test are some of the commonly performed screening tests. In-vitro colorectal cancer screening tests involve the use of cameras that capture images of the digestive tract and transfers them to the recorder tied to the waist of the patient. They are minimally invasive and can aid in timely detection of cancer. As a result, in-vitro colorectal cancer screening tests are widely performed across clinics, hospitals and diagnostics laboratories.
The increasing prevalence of colorectal cancer among the masses is one of the key factors driving the growth of the market. Moreover, rising awareness regarding the benefits of early detection and timely treatment of cancer is positively impacting the market growth. Various technological advancements, such as the integration of genetic testing in cancer screening tests, are providing a thrust to the market growth. These tests aid in early detection, developing treatment plans, preventing the spread of cancerous cells and minimizing the risks of developing associated disorders. In line with this, the increasing preference for minimally invasive (MI) diagnostic procedures to detect colorectal cancer is favoring the market growth. Other factors, including rising geriatric populations, which is more susceptible to such ailments and significant improvements in the healthcare industry, along with the implementation of various government initiatives mandating cancer screening tests, are anticipated to drive the market toward growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global In-vitro colorectal cancer screening tests market report, along with forecasts at the global, regional and country level from 2025-2033. Our report has categorized the market based on product, imaging type and end user.
Breakup by Product:
Breakup by Imaging Type:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Beckman Coulter Inc. (Danaher Corporation), Eiken Chemical Co. Ltd., Epigenomics AG, Exact Sciences Corporation, Hemosure Inc., Immunostics Inc. (Boditech Med Inc.), Medline Industries LP, Merck KGaA, Qiagen N.V., Quest Diagnostics Incorporated, R-Biopharm AG, Siemens AG and Sysmex Corporation.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Million USD |
Segment Coverage | Product, Imaging Type, End User, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Beckman Coulter Inc. (Danaher Corporation), Eiken Chemical Co. Ltd., Epigenomics AG, Exact Sciences Corporation, Hemosure Inc., Immunostics Inc. (Boditech Med Inc.), Medline Industries LP, Merck KGaA, Qiagen N.V., Quest Diagnostics Incorporated, R-Biopharm AG, Siemens AG and Sysmex Corporation |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The global in-vitro colorectal cancer screening tests market was valued at USD 1,049.2 Million in 2024.
We expect the global in-vitro colorectal cancer screening tests market to exhibit a CAGR of 4.96% during 2025-2033.
The sudden outbreak of the COVID-19 pandemic had led to postponement of elective colorectal cancer surgeries to reduce the risk of the coronavirus infection upon medical equipment, thereby negatively impacting the global market for in-vitro colorectal cancer screening tests.
The rising demand for in-vitro colorectal cancer screening tests in early detection, developing treatment plans, preventing the spread of cancerous cells, etc., is primarily driving the global in-vitro colorectal cancer screening tests market.
Based on the product, the global in-vitro colorectal cancer screening tests market can be segmented into fecal occult blood tests, biomarker tests, and CRC DNA screening tests. Currently, fecal occult blood tests hold the majority of the total market share.
Based on the imaging type, the global in-vitro colorectal cancer screening tests market has been divided into colonoscopy, proctoscopy, CT scan, ultrasound, MRI, and PET scan. Among these, colonoscopy currently exhibits a clear dominance in the market.
Based on the end user, the global in-vitro colorectal cancer screening tests market can be categorized into hospitals, clinics, diagnostic laboratories, and others. Currently, diagnostic laboratories account for the largest market share.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global in-vitro colorectal cancer screening tests market include Beckman Coulter Inc. (Danaher Corporation), Eiken Chemical Co. Ltd., Epigenomics AG, Exact Sciences Corporation, Hemosure Inc., Immunostics Inc. (Boditech Med Inc.), Medline Industries LP, Merck KGaA, Qiagen N.V., Quest Diagnostics Incorporated, R-Biopharm AG, Siemens AG, and Sysmex Corporation.